Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic

NicVAX(®), a nicotine vaccine (3’AmNic-rEPA), has been clinically evaluated to determine if higher antibody concentrations are associated with higher smoking abstinence rates and if doses and frequency of administration are associated with increased antibody response. This randomized, double-blinded...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Hatsukami, Dorothy K., Jorenby, Douglas E., Gonzales, David, Rigotti, Nancy A., Glover, Elbert D., Oncken, Cheryl A., Tashkin, Donald P., Reus, Victor I., Akhavain, Roxanne C., Fahim, Raafat E.F., Kessler, Paul D., Niknian, Minoo, Kalnik, Matthew W., Rennard, Stephen I.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4106715/
https://ncbi.nlm.nih.gov/pubmed/21270788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/clpt.2010.317
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi